Exenatide
GLP-1 receptor agonist
Also Byetta, Bydureon, Bydureon BCise, Exendin-4, Exendin 4, Synthetic exendin-4
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-26
- Route
- Injection
- Studies cited
- 2 human0 animal or cell
It is a twice-daily or weekly injection that lowers blood sugar in type 2 diabetes. Large trials back that use; it was never approved for weight loss, where it works only a little.
Sold for
Exenatide was the first GLP-1 drug, a lizard-venom peptide that opened the door to the weight-loss injectables that followed it.
Studies say
Randomized trials support its use in type 2 diabetes, an A for that indication, while for weight loss it is a weak relative of the drugs that replaced it.
Why grade A. The diabetes indication rests on a long program of randomized trials summarized in the label and on EXSCEL, a placebo-controlled cardiovascular safety trial of 14,752 patients that showed no increase in cardiovascular events over a median 3.2 years. 18 Weight loss with exenatide averages a few kilograms, well below the 15% and 22.5% seen with semaglutide and tirzepatide in their obesity trials, and it has no obesity indication. 56
FDA. Approved, with the brand products discontinued. Exenatide was approved by the FDA in 2005 as Byetta (twice-daily) and in 2012 as Bydureon (weekly; later Bydureon BCise) for glycemic control in type 2 diabetes. AstraZeneca discontinued Bydureon BCise and Byetta in the US in 2024 for business reasons; the approvals remain in force and generic exenatide is available. Exenatide has never been approved for weight loss. 13
Written from 8 cited sources. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Type 2 diabetes, weight loss
- Can a US doctor prescribe it?
- Yes, FDA approved for type 2 diabetes. It is not approved for weight loss.
- Properly tested in people?
- Yes, in large controlled trials, including one of 14,752 patients.
Evidence checklist
- Randomised controlled trial EXSCEL placebo-controlled; head-to-head trialsyes
- Human study over 100 people EXSCEL, 14,752 patientsyes
- More than one research group Registration trials plus EXSCELyes
- Clinical outcomes, not surrogate markers Cardiovascular events neutral in EXSCELyes
- Human safety data beyond case reports Median 3.2 years of safety datayes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Exenatide is a lab-made copy of exendin-4, a peptide with 39 amino acids. Researchers isolated it from the saliva of the Gila monster, a venomous lizard of the American Southwest. Exendin-4 shares about half its sequence with human GLP-1. It activates the same receptor. But it resists DPP-4, the enzyme that destroys natural GLP-1 within minutes. So it lasts longer. In 2005, Byetta became the first GLP-1 receptor agonist on the market. 2
Two forms were sold. Byetta was a twice-daily form. Bydureon was a microsphere form that releases exenatide over a week. The most recent label is for Bydureon BCise, the autoinjector version. AstraZeneca discontinued both in the US in 2024. By then, semaglutide, dulaglutide and tirzepatide led the market. 13
How it works
Exenatide activates GLP-1 receptors on pancreatic beta cells. This increases insulin release when glucose is high. It also suppresses glucagon and slows stomach emptying. It cuts appetite too, through receptors in the brainstem and hypothalamus. The twice-daily form mainly blunts the rise in glucose after meals, by slowing the stomach. The weekly form activates receptors more steadily. It affects fasting glucose more. The appetite effect is real. It is weaker than with later agonists. 12
What human research shows
The label sums up the trials that led to approval. Patients added weekly exenatide to metformin, a sulfonylurea or both. HbA1c fell by roughly 1.3 to 1.9 percentage points over 24 to 30 weeks. Patients lost 2 to 3 kg. In head-to-head trials against liraglutide and insulin glargine, exenatide did worse or about the same on HbA1c. 1
EXSCEL randomized 14,752 patients with type 2 diabetes. Most had cardiovascular disease. They got weekly exenatide or placebo. Researchers followed them for a median of 3.2 years. Major cardiovascular events occurred in 11.4% of exenatide patients and 12.2% of placebo patients. The hazard ratio was 0.91. That met the safety goal of noninferiority. It narrowly missed statistical superiority. In a secondary analysis, deaths from any cause were lower on exenatide. 8
Weight is the comparison that matters for the online market. Dedicated obesity trials gave these results. Liraglutide led to about 8% weight loss over 56 weeks. Semaglutide led to about 15% over 68 weeks. Tirzepatide led to up to 22.5% over 72 weeks. Placebo led to 2 to 3%. Exenatide never had an obesity trial. In diabetes trials, patients lost 2 to 3 kg. 4567
| Study | Model | Finding |
|---|---|---|
| EXSCEL | Humans, n=14,752, randomized double-blind placebo-controlled, median 3.2 years | Weekly exenatide did not increase cardiovascular events (hazard ratio 0.91) and narrowly missed showing a reduction. 8 |
| Bydureon BCise prescribing information | FDA label, 2024 | HbA1c reductions of about 1.3 to 1.9 points in phase 3 trials with 2 to 3 kg weight loss; boxed warning for thyroid C-cell tumors. 1 |
| From Gila monster to Byetta | Historical review | Exendin-4, isolated from Gila monster venom, shares 53% of its sequence with GLP-1 and resists DPP-4 degradation, which made it the first usable GLP-1 drug. 2 |
| STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) | Humans, n=1,961 and n=2,539, randomized placebo-controlled obesity trials | Weight loss of about 15% and up to 22.5% respectively, far above anything reported with exenatide. 5 |
Safety
Nausea is the most common side effect. A large minority of patients feel it early in treatment. Vomiting and diarrhea are less common. The weekly form causes lumps at the injection site in many patients. The microsphere carrier is the cause. The label carries a boxed warning for thyroid C-cell tumors seen in rodents. It also warns about pancreatitis and kidney injury from dehydration. It warns about low blood sugar with sulfonylureas or insulin. Allergic reactions are possible too. The kidney clears exenatide. So it is not recommended in severe kidney disease. Over three years, EXSCEL found no extra cases of pancreatitis, pancreatic cancer or medullary thyroid cancer. 18
Questions for your clinician
- Does exenatide still make sense for me now that brand products are discontinued?
- How does it compare with newer GLP-1 drugs for blood sugar and weight?
- What should I know about the thyroid tumor warning and pancreatitis?
Questions people ask
Is exenatide FDA-approved?
Yes, for type 2 diabetes. Byetta was approved in 2005 and Bydureon in 2012. The brand products were discontinued in the US in 2024. But the approvals stand. Generic exenatide is on the market. 13
Is exenatide approved for weight loss?
No. It never had a dedicated obesity trial. It produced only 2 to 3 kg of weight loss in diabetes trials. The GLP-1 drugs approved for obesity are liraglutide, semaglutide and tirzepatide. 1456
Why was Byetta discontinued?
Commercial reasons. Newer GLP-1 drugs lower glucose and weight more. They are given weekly or, in the case of dulaglutide and semaglutide, cause fewer gut side effects. AstraZeneca withdrew Bydureon BCise and Byetta from the US market in 2024. 3
Is exenatide really from lizard venom?
Yes. Researchers found exendin-4 in Gila monster saliva. Exenatide is a lab-made version with the same sequence. The lizard's version helps it manage glucose after rare large meals. 2
Is exenatide safe for the heart?
EXSCEL enrolled 14,752 patients. It showed no rise in cardiovascular events over three years and a trend toward fewer. So exenatide is seen as safe for the heart. But it has no approved use for heart benefit. 8
Citations
- FDA 2024: Bydureon BCise (exenatide extended-release) prescribing information accessdata.fda.gov
- Furman 2012, Toxicon: the development of Byetta (exenatide) from the venom of the Gila monster pubmed.ncbi.nlm.nih.gov
- UnitedHealthcare 2024: discontinuation of Bydureon BCise and Byetta uhcprovider.com
- Pi-Sunyer 2015, NEJM: a randomized controlled trial of liraglutide in weight management (SCALE) doi.org
- Wilding 2021, NEJM: once-weekly semaglutide in adults with overweight or obesity (STEP 1) doi.org
- Jastreboff 2022, NEJM: tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) doi.org
- FDA 2025: Mounjaro (tirzepatide) prescribing information accessdata.fda.gov
- Holman 2017, NEJM: effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL) doi.org